 | United States. Congress. Senate. Committee on Finance - 2003 - 88 pages
...issued. One issue that delegates left unfinished was spelled out in paragraph six: 6. We recognize that WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement. We instruct... | |
 | DAC Network on Poverty Reduction, World Health Organization - 2003 - 91 pages
...domestic market of the member authorising such use" (Article 31. f). The Doha Declaration recognised that WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement, and instructed... | |
 | Gian Luca Burci, Claude-Henri Vignes - 2004 - 262 pages
...challenge, subject to the MFN and national treatment provisions of Articles 3 and 4. 6. We recognize that WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement. We instruct... | |
 | Nico J. Schrijver, Friedl Weiss - 2004 - 750 pages
...those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics. Moreover, it recognized that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement.55 The Conference... | |
 | Ruth Macklin - 2004 - 292 pages
...from countries that have the capability of manufacturing them. Paragraph 6 states: We recognize that WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement. We instruct... | |
 | Fatoumata Jawara, Aileen Kwa - 2004 - 424 pages
...production costs. Paragraph 6 of the TRIPs and Health Declaration therefore states: 'We recognize that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPs Agreement. We instruct... | |
 | Jacques H. J. Bourgeois - 2005 - 445 pages
...the best way for the TRIPs Council to develop an expeditious solution to the difficulties faced by WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector. (a) A n amendment is not the most expeditious or workable solution Looking back at the history of the... | |
 | 2005 - 852 pages
...paragraph 6 of the Declaration to find an expeditious solution to the problem of the difficulties that WTO Members with insufficient or no manufacturing...pharmaceutical sector could face in making effective use of compulsory licensing under the TRIPS Agreement and to report to the General Council before the end... | |
 | Markus W. Gehring, Marie-Claire Cordonier Segger - 2005 - 778 pages
...issue of the export of drugs produced under compulsory license for future discussion: We recognise that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement. We instruct... | |
 | Frederick M. Abbott, Rudolf V. Van Puymbroeck - 81 pages
...challenge, subject to the MFN and national treatment provisions of Articles 3 and 4. 6. We recognize that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement. We instruct... | |
| |
We recognize that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement. We instruct the Council for TRIPS to find an... 
